Prelude Therapeutics (PRLD) Total Debt to Capital
Developing targeted therapies for lymph node cancer requires colossal investment and intellectual property protection, which hinders the expansion of new players. Meanwhile, clinical trial costs create a debt burden reaching 0.14, threatening capital dilution. The market value dynamics of the asset on GURU.Markets confirm the resilience of Prelude Therapeutics (PRLD) due to unique patents for inhibitors capable of penetrating brain tissue.
%20-%20Total%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_PRLD_-_Prelude-Therapeutics_-_Total-Debt-to-Capital "Prelude Therapeutics (PRLD) Debt to Equity: for the period 07/04/2022 - 10/30/2026 | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for Prelude Therapeutics Incorporated (PRLD)
Capital-intensive clinical trials of oncology inhibitors at Prelude Therapeutics (PRLD), coupled with a lack of revenue, create a high dependency on external financing. By analyzing the ratio of total liabilities to equity, investors assess the proportion of debt within the asset structure, which allows them to determine the risk of liquidity gaps and the business's resilience to rising interest rates amid negative operating leverage.